<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880618</url>
  </required_header>
  <id_info>
    <org_study_id>360049-001</org_study_id>
    <nct_id>NCT02880618</nct_id>
  </id_info>
  <brief_title>BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction</brief_title>
  <acronym>HFrEF</acronym>
  <official_title>BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM
      NEO System in the commercial setting in subjects recently implanted under the CE-Marked
      indication for heart failure with reduced ejection fraction (HFrEF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Change in New York Heart Association Functional Classification at 6 months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Six Minute Hall Walk from Baseline to 6 months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular Mass Index Change from Baseline to 6 Months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Biomarkers from Baseline to 6 months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
    <description>e.g. NT-pro BNP, eGFR, Troponin HsT, Cystatin C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Hospitalizations over Follow-Up</measure>
    <time_frame>12 months post-implant</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Barostim Neo™ System</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects can be included in the Heart Failure with Reduced Ejection Fraction Registry if
        they were implanted in the past 30 days and meet the CE-Mark approved indications, and are
        not contraindicated, for the BAROSTIM NEO System in the treatment of heart failure.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has signed an EC approved informed consent form

          -  Has been treated with the appropriate heart failure guideline directed therapy

          -  Has been implanted with the BAROSTIM NEO System in the past 30 days

          -  NYHA III and,

          -  LVEF ≤ 35%

        Exclusion Criteria:

          -  Bilateral carotid bifurcations located above the level of the mandible

          -  Baroreflex failure or autonomic neuropathy

          -  Uncontrolled, symptomatic cardiac bradyarrhythmias

          -  Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to
             be greater than 50%

          -  Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Müller-Ehmsen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asklepios Klinik Altona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CVRx Vice President of Clinical Research</last_name>
    <phone>763-416-2876</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgct Wellmann</last_name>
      <phone>05721-973327</phone>
      <email>Bwellmann@hdz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>Klaus-Jurgen Gutleben</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Bettin</last_name>
      <phone>+49-3338-694604</phone>
      <email>d.bettin@immanuel.de</email>
    </contact>
    <investigator>
      <last_name>Christian Butter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MVZ am Kuchwald GmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicitas Fröhlich-Grimm</last_name>
      <phone>+ 49 371 37421354</phone>
      <email>f.froehlich-grimm@herzcentrum-chemnitz.de</email>
    </contact>
    <investigator>
      <last_name>Wilfried Danschel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Justus-Leibig University Giessen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Hellwig</last_name>
      <phone>0641-985-42632</phone>
      <email>gabriele.hellwig@med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Jorn Schmitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Kliniken Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Neumann</last_name>
      <phone>+49 401818818635</phone>
      <email>chris.neumann@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Jochen Müller-Ehmsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albertinen-Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22457</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cramer Eva</last_name>
      <phone>0049-40-55886722</phone>
      <email>eva.cramer@albertinen.de</email>
    </contact>
    <investigator>
      <last_name>Nagele Herbert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hoschshule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Juergens</last_name>
      <phone>+49 511/ 532 6054</phone>
      <email>juergens.antje@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Christian Veltmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anika Struve</last_name>
      <phone>+49 431 500 22915</phone>
      <email>anika.struve@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Hendrik Bonnemeier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatjana Schewior</last_name>
      <phone>49-221-478-88273</phone>
      <email>Tatjana.schewior@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Marcel Halbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Dietrich</last_name>
      <phone>+49 (341) 97 12 408</phone>
      <email>jenny.dietrich@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Janine Starke</last_name>
      <phone>+49 (341) 97 12 443</phone>
      <email>janine.starke@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Neef</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg gGmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Reichelt</last_name>
      <phone>03419094561</phone>
      <email>susanne.reichelt@sanktgeorg.de</email>
    </contact>
    <investigator>
      <last_name>Norbert Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marien-Krankenhaus Siegen gem. GmbH</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Blanke</last_name>
      <phone>02711-231-1215</phone>
      <email>c.blanke@marienkrankenhaus.com</email>
    </contact>
    <investigator>
      <last_name>Michael Buerke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital and MVS Maria-Hilf Stadtlohn GmbH</name>
      <address>
        <city>Stadtlohn</city>
        <zip>489703</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Fitz</last_name>
      <phone>02563-912-6370</phone>
      <email>b.fitz@kmh-stadtlohn.de</email>
    </contact>
    <investigator>
      <last_name>Alessandro Cuneo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Landkreis Tuttlingen</name>
      <address>
        <city>Tuttlingen</city>
        <zip>78532</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Weber</last_name>
      <phone>07461 97 1415</phone>
      <email>i.weber@klinikum-tut.de</email>
    </contact>
    <investigator>
      <last_name>Michael Kotzerke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione di Ricerca e Cura &quot;Giovanni Paolo II&quot;</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celestino Sardu</last_name>
      <phone>+39 0874-312361</phone>
      <email>drsarducele@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eugenio Caradonna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015 Jun;3(6):487-496. doi: 10.1016/j.jchf.2015.02.006. Epub 2015 May 14.</citation>
    <PMID>25982108</PMID>
  </reference>
  <reference>
    <citation>Zile MR, Abraham WT, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015 Oct;17(10):1066-74. doi: 10.1002/ejhf.299. Epub 2015 Jun 10.</citation>
    <PMID>26011593</PMID>
  </reference>
  <reference>
    <citation>Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, Lovett EG, Mancia G, Grassi G. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail. 2014 Sep;16(9):977-83. doi: 10.1002/ejhf.138. Epub 2014 Jul 28.</citation>
    <PMID>25067799</PMID>
  </reference>
  <reference>
    <citation>Gronda E, Seravalle G, Trevano FQ, Costantino G, Casini A, Alsheraei A, Lovett EG, Vanoli E, Mancia G, Grassi G. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction. J Hypertens. 2015 Aug;33(8):1704-8. doi: 10.1097/HJH.0000000000000603.</citation>
    <PMID>26132760</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Reduced ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

